Metrics Inc. Appoints Director of Pharmaceutical Development
Joe Cobb, CPIP, will oversee the company's formulation development, potent handling capabilities.
Greenville, NC, February 06, 2013 --(PR.com)-- Metrics Inc. has appointed Joseph E. “Joe” Cobb Jr., CPIP, as director of pharmaceutical development.
In this new position, Cobb will manage all aspects of projects at Metrics that involve early-phase solid oral dosage development. He also will oversee the company’s potent and cytotoxic drug development services, which include a dedicated and segregated potent facility.
“Joe is a smart and capable leader who has been instrumental in guiding the success and growth of Metrics’ formulation development capabilities,” said Phil Hodges, president of Metrics. “With these new responsibilities, Joe will bring to his role the same thoughtfulness and resourcefulness.”
With more than 20 years of industry experience, Cobb holds the highly respected Certified Pharmaceutical Industry Professional credential from ISPE, the only competency-based international certification for pharmaceutical professionals. He joined Metrics in 2002 and earned his chemical engineering degree from The Ohio State University.
Metrics Inc. is a full-service global pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for solid oral dosage forms.
The company’s areas of expertise include quality pharmaceutical formulation development; first-time-in-man (FTIM) formulations; clinical material manufacturing (CTM) for Phase I, II and III trials; and analytical method development and validation services leading to commercial scale manufacturing.
Within the past five years, Metrics has conducted more than 75 FTIM studies while simultaneously producing 700-plus batches of CTM.
Metrics’ technical capabilities include highly potent, cytotoxic and unstable compounds, Schedule II-V controlled substances, and products with poor bioequivalence – for which we offer an impressive proprietary portfolio of advanced delivery methods.
Our work supports investigational new drug (IND), new drug (NDA) and abbreviated new drug (ANDA) submissions made to worldwide regulatory agencies on behalf of clients ranging from internationally renowned corporations to small virtual companies.
Based in Greenville, N.C., Metrics Inc. proudly operates as a subsidiary of Mayne Pharma Group Limited. To learn more, visit metricsinc dot com.
In this new position, Cobb will manage all aspects of projects at Metrics that involve early-phase solid oral dosage development. He also will oversee the company’s potent and cytotoxic drug development services, which include a dedicated and segregated potent facility.
“Joe is a smart and capable leader who has been instrumental in guiding the success and growth of Metrics’ formulation development capabilities,” said Phil Hodges, president of Metrics. “With these new responsibilities, Joe will bring to his role the same thoughtfulness and resourcefulness.”
With more than 20 years of industry experience, Cobb holds the highly respected Certified Pharmaceutical Industry Professional credential from ISPE, the only competency-based international certification for pharmaceutical professionals. He joined Metrics in 2002 and earned his chemical engineering degree from The Ohio State University.
Metrics Inc. is a full-service global pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for solid oral dosage forms.
The company’s areas of expertise include quality pharmaceutical formulation development; first-time-in-man (FTIM) formulations; clinical material manufacturing (CTM) for Phase I, II and III trials; and analytical method development and validation services leading to commercial scale manufacturing.
Within the past five years, Metrics has conducted more than 75 FTIM studies while simultaneously producing 700-plus batches of CTM.
Metrics’ technical capabilities include highly potent, cytotoxic and unstable compounds, Schedule II-V controlled substances, and products with poor bioequivalence – for which we offer an impressive proprietary portfolio of advanced delivery methods.
Our work supports investigational new drug (IND), new drug (NDA) and abbreviated new drug (ANDA) submissions made to worldwide regulatory agencies on behalf of clients ranging from internationally renowned corporations to small virtual companies.
Based in Greenville, N.C., Metrics Inc. proudly operates as a subsidiary of Mayne Pharma Group Limited. To learn more, visit metricsinc dot com.
Contact
Metrics, Inc.
Karen Stinneford
919-833-9102
http://www.metricsinc.com
Karen Stinneford
919-833-9102
http://www.metricsinc.com
Contact
Categories